febuxostat多少钱？

(Febuxostat) is a new non-purine xanthine oxidase (XO) selective inhibitor that works by reducing blood urate concentration. It is completely absorbed orally and has high bioavailability. Food and antacids have no significant impact on its absorption. In April 2008, the European EMEA approved the marketing of febuxostat tablets. In February 2009, the US FDA approved the marketing of febuxostat tablets. It is the first new anti-gout drug approved by the FDA in the past 40 years.

In clinical practice, no matter what type of drug it is, when it is used to treat some diseases, everyone is more concerned about the cost-effectiveness of the drug, especially the price of the drug. So, how much does a box of feburic cost?

The price of the original drug Febuxostat in Japan is relatively high, about $1,500 per box. The price of febuxostat in China is 10$/tablet, one tablet a day, which is about 300 per month. However, some patients have poor absorption and need two tablets a day, which is about 600 per month. Gout requires febuxostat for a long time, which is not a small number. The Indian generic version of Febuxostat has the same efficacy as the original drug. The specification is 80mg*30 tablets/box, and its price is about $200.

The starting dose of feburic is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl (approximately 360 μmol/L) after 2 weeks, it is recommended that the dose be increased to 80 mg once a day.

Food and antacid effects do not need to be considered when administering the drug. Patients with mild or moderate hepatic insufficiency (Child-Pugh Class A, B) do not need to adjust the dosage. Patients with severe hepatic insufficiency (Child-Pugh Class C) should use feburic with caution.

Special populations: Patients with hepatic impairment: No dose adjustment is required for patients with mild or moderate hepatic impairment (Child-Pugh A, B). The efficacy and safety of feburic (febuxostat) in patients with severe hepatic insufficiency (Child-Pugh class C) have not been studied, so feburic (febuxostat) should be used with caution in these patients. Patients with renal insufficiency: Patients with mild or moderate renal insufficiency (Clcr30-89 ml/min) do not need to adjust the dosage. The recommended starting dose of feburic is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl after 2 weeks, it is recommended that the dose be increased to 80 mg once a day. There are insufficient study data in patients with severe renal insufficiency (Clcr <30ml/min), so feburic (febuxostat) should be used with caution in these patients. Uric Acid Levels Two weeks after starting treatment with febuxostat, it is possible to assess whether the serum uric acid level has reached the target value (less than 6 mg/dl).